Zobrazeno 1 - 10
of 132
pro vyhledávání: '"B. Tocque"'
Autor:
V Sierra, Emmanuel Conseiller, M Maratrat, C Venot, B Tocque, L Debussche, D Landais, L Bracco
Publikováno v:
Journal of Clinical Investigation. 101:120-127
The clinical potential of the p53 tumor suppressor gene is being evaluated currently for gene therapy of cancer. We have built a variant of wild-type p53, chimeric tumor suppressor 1 (CTS1), in which we have replaced the domains that mediate its inac
Autor:
N. Fromage, B. Tocque, Fabrice Cornille, Christiane Garbay, Nathalie Jullian, Yinshan Yang, Bernard-Pierre Roques, M. Duchesne
Publikováno v:
The EMBO Journal. 13:1270-1279
Src homology 3 (SH3) domains are found in numerous cytoplasmic proteins involved in intracellular signal transduction. We used 2-D 1H NMR to determine the structure of the SH3 domain of the guanosine triphosphatase-activating protein (GAP), an essent
Publikováno v:
Journal of Biological Chemistry. 267:16155-16160
p21ras plays an important role in the control of cell proliferation. The molecular mechanisms implicated are unknown. We report that the injection of oncogenic Lys12 Ras into Xenopus laevis oocytes promoted the activation of mitogen-activated protein
Autor:
M E, Million, P, Mailliett, H, Chen, G, Bashiardes, J, Boiziau, F, Parker, A, Commerçon, B, Tocque, B P, Roques, C, Garbay
Publikováno v:
Anti-cancer drug design. 11(2)
In order to design new potent inhibitors of the epidermal growth factor receptor (EGF-R) associated protein tyrosine kinase (PTK) activity as antitumor agents, several families of phenylhydroquinone derivatives were synthesized. Some of these compoun
Autor:
H, Chen, G, Bashiardes, P, Mailliet, A, Commercon, F, Sounigo, J, Boiziau, F, Parker, B, Tocque, B P, Roques, C, Garbay
Publikováno v:
Anti-cancer drug design. 11(1)
In order to obtain non-degradable and more potent protein-tyrosine kinase inhibitors, derived from the 5-(2,5-dihydroxybenzyl)-aminosalicylates already described, we have developed a new series of 5-(2,5-dihydroxybenzyl)phenylamines. The compounds, d
Publikováno v:
Oncogene. 11(11)
The p53 tumour-suppressor guards the genome in response to genotoxic stress by transcriptional regulation of genes involved in cell-cycle control, DNA replication, repair and apoptosis such as p21, GADD45, bax and mdm2 (Cox and Lane, 1995). Mdm2 is c
Publikováno v:
Methods in enzymology. 255
Autor:
F, Schweighoffer, M, Faure, I, Fath, M C, Chevallier-Multon, F, Apiou, B, Dutrillaux, E, Sturani, M, Jacquet, B, Tocque
Publikováno v:
Oncogene. 8(6)
A critical step in the activation of cellular Ras is the release of bound GDP. Oligonucleotide primers derived from a mouse cDNA sequence homologous to the Saccharomyces cerevisiae CDC25 gene product were used to screen a human brain cDNA library. Th
The Saccharomyces cerevisiae gene product SDC25 C-domain functions as an oncoprotein in NIH3T3 cells
Autor:
I, Barlat, F, Schweighoffer, M C, Chevallier-Multon, M, Duchesne, I, Fath, D, Landais, M, Jacquet, B, Tocque
Publikováno v:
Oncogene. 8(1)
Ras proteins in mammalian cells cycle between a GTP-bound 'on' state and a GDP-bound 'off' state. Activation of Ras p21 results from the dissociation of tightly bound GDP and the exchange of bound GDP for GTP. A guanine nucleotide exchange factor is
Autor:
B, Tocque
Publikováno v:
Pathologie-biologie. 39(9)